Integral Diagnostics Limited
IDX.ASXHealth Care
Provider of medical imaging services across Australia and New Zealand.
Market Data
$2.060
-0.0%$772.2M
55.5x
$0.037
3.53%
-0.2%
Latest Earnings
FY26 Half Year Results App4D and Interim Report
24 February 2026
Integral Diagnostics reported strong HY26 results driven by the Capitol Health acquisition, with revenue up 55.6% to $393.5M and EBITDA surging 91.4% to $67.1M. The company achieved solid organic growth of 6.9% on a constant currency basis and declared an interim dividend of 3.3 cents, up from 2.5 cents previously. Integration synergies from the Capitol merger are exceeding expectations at $14M+ annually. Key points: Capitol Health merger synergies significantly exceeding initial expectations at $14M+ annually vs $10M+ originally expected; Strong organic revenue growth of 6.9% on constant currency basis excluding closed/sold sites; Improved Group Operating EBITDA margin of 20.6%, up 230 bps vs HY25
Recent Announcements
Becoming a substantial holder
I appreciate you sharing this, but the text appears to be encoded or reversed (reading "For personal use only" backwards multiple times). Without being able to read the actual announcement content clearly, I cannot provide an accurate summary of who became a substantial holder, what transactions occurred, or the relevant shareholding percentages. Could you please provide the announcement in readable format? Once I can see the actual content, I'll be happy to summarize it according to your requi
Becoming a substantial holder
Australian Retirement Trust Pty LTD ATF Australian Retirement Trust became a substantial holder (5.043%).
Ceasing to be a substantial holder
Australian Retirement Trust Pty LTD ATF Australian Retirement Trust ceased to be a substantial holder.
Becoming a substantial holder
controlled entities named in the list of 4 pages annexed to this notice and marked A (Daiichi Controlled Entities) became a substantial holder.
Becoming a substantial holder
Australian Retirement Trust Pty LTD ATF Australian Retirement Trust became a substantial holder (5.016%).
FY26 Half Year Results Investor Presentation
IDX delivered strong 1H FY26 results with revenue growing 55.6% to $393.5M including six months contribution from Capitol merger. Operating EBITDA increased 75.6% to $81.1M with margin expansion of 230bps to 20.6%, while synergies of $14M+ exceeded initial expectations. The company is well positioned for continued growth from MRI deregulation and lung cancer screening programs. Key points: Strong revenue growth of 55.6% to $393.5M including Capitol contribution; Operating EBITDA margin improved 230bps to 20.6% with 75.6% growth to $81.1M; Capitol merger synergies of $14M+ exceeded initial $10M expectations
FY26 Half Year Results Media Release
Integral Diagnostics delivered strong 1H FY26 results with revenue up 55.6% to $393.5M and Operating EBITDA growing 75.6% to $81.1M at an improved margin of 20.6%. The Capitol Health merger integration is exceeding expectations with $14.0M+ in annual synergies realized versus initial expectations of $10.0M. The company maintained strong guidance for FY26 Operating EBITDA margin of ~21.0% with continued revenue growth expected. Key points: Strong Operating EBITDA margin improvement to 20.6%, up 230 basis points; Capitol Health merger integration exceeding expectations with $14.0M+ annual synergies vs $10.0M initial target; Strong balance sheet with reduced leverage to 2.5x Net Debt/EBITDA ratio
FY26 Half Year Results App4D and Interim Report
Integral Diagnostics reported strong HY26 results driven by the Capitol Health acquisition, with revenue up 55.6% to $393.5M and EBITDA surging 91.4% to $67.1M. The company achieved solid organic growth of 6.9% on a constant currency basis and declared an interim dividend of 3.3 cents, up from 2.5 cents previously. Integration synergies from the Capitol merger are exceeding expectations at $14M+ annually. Key points: Capitol Health merger synergies significantly exceeding initial expectations at $14M+ annually vs $10M+ originally expected; Strong organic revenue growth of 6.9% on constant currency basis excluding closed/sold sites; Improved Group Operating EBITDA margin of 20.6%, up 230 bps vs HY25
Get real-time alerts for IDX
Receive AI-powered earnings summaries and instant notifications when Integral Diagnostics Limited releases results.
Register Free